Analyst: This Pharma Stock Could Triple

The brokerage firm also initiated coverage with an "outperform" rating

Dec 7, 2018 at 10:35 AM
facebook twitter linkedin


RBC initiated coverage on Corbus Pharmaceuticals Holdings Inc (NASDAQ:CRBP) with an "outperform" rating and $23 price target -- a 245% premium to last night's close. The analyst in coverage waxed optimistic over the long-term upside potential of the drugmaker's lead drug lenabasum, which is currently undergoing trials in patients with cystic fibrosis and systemic sclerosis.

In response, CRBP is trading up 5.8% at $7.05. The shares shot nearly 54% higher back on Sept. 20, on the back of a well-received licensing deal, but have since been stuck beneath a trendline connecting lower highs from early October. Today's pop has the shares aiming for a close in positive year-to-date territory, having entered 2018 trading at $7.10.

crbp stock daily price chart on dec 7

Analysts have remained upbeat on the shares, with 100% of those in coverage maintaining a "buy" or better rating. Plus, the average 12-month price target sits all the way up at $23.33.

Short sellers, on the other hand, have been actively targeting CRBP stock. Short interest on the pharma name is up almost 82% since the start of the year, to 14.12 million shares, and hit a record high 14.53 million shares in the Nov. 1 reporting period. The current number of shorted shares accounts for 26.3% of the equity's available float, or 15 times the average daily pace of trading.
 

If you are not making money with options, you aren’t buying options like this…

There is no options strategy that more perfectly approaches trading the fastest moving and most volatile stocks available in the marketplace than this one. In fact, there is no strategy that better utilizes put options for optimal returns and a real trading edge over other traders in the exact same market. New options traders fail out at an incredible rate without proper trade research, execution timing, and option picking. Capitalize on Schaeffer’s 100+ years of options trading excellence with the most coveted product launch in company history. Don't waste another second... join us right now before the next round of trades are released!

 


 


 
Special Offers from Schaeffer's Trading Partners